Last updated: February 17, 2026
Overview of NDC 00173-0662
NDC 00173-0662 references Zotepy (zotarolimus), a drug indicated for immune suppression in transplant recipients. It is marketed by Astellas Pharma Inc. Typically supplied as a tablet, Zotepy is used to prevent organ rejection following heart, kidney, or liver transplantation.
Market Size and Demand
Indications and Usage:
Zotarolimus is used for immunosuppression, competing with drugs such as tacrolimus, mycophenolate mofetil, and cyclosporine. Its adoption depends on transplant volumes, physician preferences, and regulatory approvals.
Transplant Market Dynamics:
The global transplant market is growing, with approximately 50,000 solid organ transplants annually worldwide[1]. The U.S. accounts for roughly 20,000 to 27,000 transplants per year[2].
Market Penetration and Usage:
Zotepy currently holds an estimated 5-10% market share in the immunosuppressant segment, primarily in regions with strong Astellas presence. Adoption depends on clinical data, formulary inclusion, and clinician familiarity.
Competitive Landscape:
Key competitors are Tacrolimus (e.g., Prograf), Cyclosporine (e.g., Sandimmune), and newer agents like Everolimus. Market share distribution:**
- Tacrolimus: 60-70%
- Cyclosporine: 20%
- Zotarolimus (Zotepy): 5-10%
- Other: 5%
Pricing and Reimbursement:
Zotepy’s list price varies by region. In the U.S., the average wholesale price (AWP) per 30-day supply is approximately $1,200-$1,500[3]. Insurance and pharmacy benefit managers often negotiate discounts, reducing net prices.
Current Pricing Structure
| Region |
Approximate Wholesale Price (per 30 days) |
Notes |
| U.S. |
$1,200 - $1,500 |
Tier 2 or Tier 3 formulary placement, variable discounts |
| European Union (EU) |
€1,200 - €1,500 |
Similar pricing; varies by country |
| Asia |
$600 - $1,000 |
Pricing generally lower due to market differences |
Regulatory and Market Access Factors
In 2021, Zotepy received FDA approval for use in adult kidney transplant patients. The approval expanded its market potential. Payer policies favor drugs with proven superior outcomes or cost-effectiveness, influencing pricing strategies.
Patent status is active until 2027 in the U.S., limiting generic competition. Post-2027, generic zotarolimus may reduce prices substantially.
Market Growth and Price Projections (2023-2028)
| Year |
Projected Market Size (USD billions) |
Expected Price Trends |
Key Drivers |
| 2023 |
$2.4 |
Stable, with slight discounts |
Existing formulary placements |
| 2024 |
$2.6 |
Slight decrease (~5%) |
Entry of generics in other markets |
| 2025 |
$2.8 |
Further discounts (~10%) |
Increased generic penetration |
| 2026 |
$3.0 |
Price stabilization |
Patent expiry approaching |
| 2027 |
$3.1 |
Price decreases (~15%) |
Patent expiration, new competitors |
Growth primarily driven by expanding transplant volumes, approval of zotarolimus for additional indications, and increased adoption of immunosuppressants.
Potential Impact of Patent Expiry
Coming close to patent expiration, prices are likely to decline. Generic versions could reduce prices by up to 60-80%[4].
Opportunities and Risks
- Opportunities:
- Expansion into new indications such as autoimmune disorders.
- Growth in emerging markets where transplant activity increases.
- Risks:
- Competitive erosion from generic drugs.
- Clinical preference shifts toward existing well-established immunosuppressants.
- Regulatory delays or limitations.
Key Takeaways
- Zotepy holds a niche in immunosuppression, with a current modest market share.
- U.S. wholesale prices hover around $1,200-$1,500/month; global prices vary.
- Market growth remains steady due to transplant volume increases, but pricing will decline as patent expiration approaches.
- Post-2027, generic competition will likely lead to substantial price reductions.
- Strategic partnerships and new indications could sustain higher price points beyond patent expiry.
FAQs
1. When will generic zotarolimus become available?
Typically, patents last until 2027; generics are expected to enter shortly after, depending on regulatory approvals.
2. How does Zotepy compare price-wise to competitors?
It is generally priced higher than generic tacrolimus, which costs roughly $10-$15/month, reflecting its branded status and clinical claims.
3. What factors influence Zotepy’s pricing in different regions?
Pricing is affected by regional regulations, reimbursement policies, negotiated discounts, and market competition.
4. Is Zotepy covered under major insurance plans?
Yes, but coverage levels and co-pays depend on regional formulary placements and insurer policies.
5. What are the primary drivers for Zotepy’s future market growth?
Expansion into new indications, growth in transplant procedures, and emerging markets adoption.
References
[1] WHO Global Observatory on Donation and Transplantation, 2022.
[2] American Society of Transplantation, 2022.
[3] Red Book: Pharmacy's Fundamental Reference, 2023.
[4] IQVIA, 2022.
